Israel-listed cell therapy biotech Bonus Biogroup increases shares offered by 25% ahead of $19 million US IPO
I'm LongbridgeAI, I can summarize articles.Bonus Biogroup, an Israeli biotech firm, has increased its IPO offering by 25%, now aiming to raise $19 million by selling 3.8 million ADSs priced between $4 and $6. The company, listed on the Tel Aviv Stock Exchange as "BONS," is developing cell therapies for bone regeneration and respiratory issues. Its lead products include BonoFill and MesenCure, both of which are in various stages of clinical trials. Bonus Biogroup plans to list on Nasdaq under the same symbol, with D. Boral Capital as the bookrunner.
Bonus Biogroup, a phase 2 Israeli biotech developing cell therapies for bone regeneration and respiratory indications, raised the proposed deal size for its upcoming IPO on Tuesday. The company is currently listed on the Tel Aviv Stock Exchange under the symbol "BONS."
The Haifa, Israel-based company now plans to raise $19 million by offering 3.8 million ADSs at a price range of $4 to $6. The company had previously filed to offer 3 million ADSs at the same range.
The company's two lead product candidates are BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage. BonoFill completed a Phase 2 trial in maxillofacial bone defects in the upper and lower jaw bones for sinus augmentation and void filling, and is currently in a Phase 2 trial in defects in long and short limb bones incapable of self-healing or untreatable by standard techniques, with interim results expected in 2026. MesenCure completed a Phase 2 trial for pulmonary manifestations of COVID in severely ill patients in 2022, and in February received clearance for a Phase 3 trial. The company plans to initiate a trial of MesenCure in all-cause respiratory distress in 2026.
Bonus Biogroup was founded in 1981. It plans to list on the Nasdaq under the symbol BONS. D. Boral Capital is the sole bookrunner on the deal.